High rate of linezolid intermediate susceptibility and resistance among enteric vancomycin-resistant Enterococcus (VRE) recovered from hospitalized patients actively screened for VRE colonization

Infect Control Hosp Epidemiol. 2019 Jul;40(7):821-822. doi: 10.1017/ice.2019.116. Epub 2019 May 15.

Authors

Affiliations

¹ Department of Pharmacy Services, Aurora Health Care,Milwaukee,Wisconsin.
² Department of Microbiology, ACL Laboratories,West Allis,Wisconsin.
³ Department of Abdominal Transplant, Aurora Health Care,Milwaukee,Wisconsin.
⁴ Department of Critical Care Medicine, Aurora Health Care,Milwaukee,Wisconsin.
⁵ Infectious Diseases Section, Aurora St Luke's Medical Center,Milwaukee,Wisconsin.

PMID: 31088583
DOI: 10.1017/ice.2019.116

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Cross Infection / drug therapy*
Cross Infection / microbiology
Daptomycin / pharmacology*
Female
Gram-Positive Bacterial Infections / drug therapy*
Gram-Positive Bacterial Infections / microbiology
Humans
Linezolid / pharmacology*
Male
Microbial Sensitivity Tests
Middle Aged
Risk Factors
Vancomycin-Resistant Enterococci / drug effects*
Vancomycin-Resistant Enterococci / isolation & purification

Substances

Linezolid
Daptomycin